| Year |
Citation |
Score |
| 2024 |
Ding J, Lu HH, Levi DM. Absolute and relative disparity mechanisms revealed by an equivalent noise analysis. Scientific Reports. 14: 6863. PMID 38514715 DOI: 10.1038/s41598-024-57406-2 |
0.396 |
|
| 2022 |
Wang M, Ding J, Levi DM, Cooper EA. The effect of spatial structure on binocular contrast perception. Journal of Vision. 22: 7. PMID 36326743 DOI: 10.1167/jov.22.12.7 |
0.419 |
|
| 2021 |
Chopin A, Silver MA, Sheynin Y, Ding J, Levi DM. Transfer of Perceptual Learning From Local Stereopsis to Global Stereopsis in Adults With Amblyopia: A Preliminary Study. Frontiers in Neuroscience. 15: 719120. PMID 34630011 DOI: 10.3389/fnins.2021.719120 |
0.641 |
|
| 2021 |
Lev M, Ding J, Polat U, Levi DM. Nearby contours abolish the binocular advantage. Scientific Reports. 11: 16920. PMID 34413354 DOI: 10.1038/s41598-021-96053-9 |
0.427 |
|
| 2020 |
Ding J, Levi DM. A unified model for binocular fusion and depth perception. Vision Research. 180: 11-36. PMID 33359897 DOI: 10.1016/j.visres.2020.11.009 |
0.411 |
|
| 2020 |
Xia ZJ, Ji YC, Sun DQ, Peng X, Gao YL, Fang YF, Zhao XD, Wang WB, Ding J, Geng MY, Ai J. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors. Acta Pharmacologica Sinica. PMID 32918045 DOI: 10.1038/S41401-020-00513-3 |
0.323 |
|
| 2020 |
Martín S, Portela JA, Ding J, Ibarrondo O, Levi DM. Evaluation of a Virtual Reality implementation of a binocular imbalance test. Plos One. 15: e0238047. PMID 32822405 DOI: 10.1371/Journal.Pone.0238047 |
0.462 |
|
| 2020 |
Wang L, Ai J, Shen Y, Zhang H, Peng X, Huang M, Zhang A, Ding J, Geng M. Corrigendum to "SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo" [Cancer Lett. 351 (2014) 143-50]. Cancer Letters. PMID 32475789 DOI: 10.1016/J.Canlet.2020.05.010 |
0.32 |
|
| 2020 |
Xiang HY, Chen YH, Wang Y, Zhang X, Ding J, Meng LH, Yang CH. Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo[2,1-f][1,2,4]triazine derivatives. Bioorganic & Medicinal Chemistry Letters. 127194. PMID 32317209 DOI: 10.1016/J.Bmcl.2020.127194 |
0.316 |
|
| 2020 |
Chen Y, Bai G, Ning Y, Cai S, Zhang T, Song P, Zhou J, Duan W, Ding J, Xie H, Zhang H. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. European Journal of Medicinal Chemistry. 190: 112092. PMID 32014679 DOI: 10.1016/J.Ejmech.2020.112092 |
0.337 |
|
| 2020 |
Li L, Huang M, Li L, Chen Y, Tang S, Su Y, Dong R, Ding J, Geng M. Abstract 3760: HH2710, a highly potent and selective erk1/2 inhibitor for the treatment of mapk mutant tumors Immunology. 80: 3760-3760. DOI: 10.1158/1538-7445.Am2020-3760 |
0.343 |
|
| 2019 |
Zhang SW, Gong CJ, Su MB, Chen F, He T, Zhang YM, Shen QQ, Su Y, Ding J, Li J, Chen Y, Nan FJ. Synthesis and in vitro and in vivo biological evaluation of tissue-specific bisthiazole Histone deacetylase (HDAC) inhibitors. Journal of Medicinal Chemistry. PMID 31855601 DOI: 10.1021/Acs.Jmedchem.9B01792 |
0.331 |
|
| 2019 |
Peng X, Hou P, Chen Y, Dai Y, Ji Y, Shen Y, Su Y, Liu B, Wang Y, Sun D, Jiang Y, Zha C, Xie Z, Ding J, Geng M, et al. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models. Journal of Experimental & Clinical Cancer Research : Cr. 38: 372. PMID 31438996 DOI: 10.1186/S13046-019-1357-Y |
0.321 |
|
| 2019 |
Lai MZ, Song PR, Dou D, Diao YY, Tong LJ, Zhang T, Xie H, Li HL, Ding J. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors. Acta Pharmacologica Sinica. PMID 31316181 DOI: 10.1038/S41401-019-0250-8 |
0.363 |
|
| 2019 |
Chen YH, Lv H, Shen N, Wang XM, Tang S, Xiong B, Ding J, Geng MY, Huang M. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells. Acta Pharmacologica Sinica. PMID 31316177 DOI: 10.1038/S41401-019-0268-Y |
0.35 |
|
| 2019 |
Shen J, Zhang T, Zhu SJ, Sun M, Tong L, Lai M, Zhang R, Xu W, Wu R, Ding J, Yun CH, Xie H, Lu X, Ding K. Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S). Journal of Medicinal Chemistry. PMID 31298540 DOI: 10.1021/Acs.Jmedchem.9B00576 |
0.347 |
|
| 2019 |
Xie S, Wei F, Sun YM, Gao YL, Pan LL, Tan MJ, Wang SD, Ding J, Chen Y. EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma. Haematologica. PMID 31289198 DOI: 10.3324/Haematol.2019.222935 |
0.313 |
|
| 2019 |
Li Q, Zhang T, Li S, Tong L, Li J, Su Z, Feng F, Sun D, Tong Y, Wang X, Zhao Z, Zhu L, Ding J, Li H, Xie H, et al. Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFR. Acs Medicinal Chemistry Letters. 10: 869-873. PMID 31223440 DOI: 10.1021/Acsmedchemlett.8B00564 |
0.327 |
|
| 2019 |
Diao Y, Fang X, Song P, Lai M, Tong L, Hao Y, Dou D, Liu Y, Ding J, Zhao Z, Xie H, Li H. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry. PMID 31221612 DOI: 10.1016/J.Bmc.2019.06.023 |
0.351 |
|
| 2019 |
Zhang KL, Shen QQ, Fang YF, Sun YM, Ding J, Chen Y. AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition. Acta Pharmacologica Sinica. PMID 31171828 DOI: 10.1038/S41401-019-0248-2 |
0.313 |
|
| 2019 |
Han G, Qing L, Wu M, Wang Y, Liu Y, Liu X, Wang Z, Ding J, Meng LH, Wang Q. Design, synthesis, and biological activity evaluation of (-)-6-O-desmethylantofine analogues as potent anti-cancer agents. Bioorganic & Medicinal Chemistry. PMID 31171403 DOI: 10.1016/J.Bmc.2019.05.030 |
0.353 |
|
| 2019 |
Wang Y, Li X, Liu X, Chen Y, Yang C, Tan C, Wang B, Sun Y, Zhang X, Gao Y, Ding J, Meng L. Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer. Cancer Biology & Medicine. 16: 66-83. PMID 31119047 DOI: 10.20892/J.Issn.2095-3941.2018.0361 |
0.301 |
|
| 2019 |
Cui JJ, Ji KL, Liu HC, Zhou B, Liu QF, Xu CH, Ding J, Zhao JX, Yue JM. Cytotoxic Tigliane Diterpenoids from Croton damayeshu. Journal of Natural Products. PMID 31117522 DOI: 10.1021/Acs.Jnatprod.9B00042 |
0.304 |
|
| 2019 |
Guo Z, Zhang Z, Yang H, Cao D, Xu X, Zheng X, Chen D, Wang Q, Li Y, Li J, Du Z, Wang X, Chen L, Ding J, Shen J, et al. Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 Against Acute Myeloid Leukemia. Journal of Medicinal Chemistry. PMID 31117515 DOI: 10.2210/Pdb6Izq/Pdb |
0.344 |
|
| 2019 |
Leung EL, Luo LX, Li Y, Liu ZQ, Li LL, Shi DF, Xie Y, Huang M, Lu LL, Duan FG, Huang JM, Fan XX, Yuan ZW, Ding J, Yao XJ, et al. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant non-small cell lung cancer. International Journal of Cancer. PMID 30786019 DOI: 10.1002/Ijc.32222 |
0.336 |
|
| 2019 |
Liu XL, Liu JL, Xu YC, Zhang X, Wang YX, Qing LH, Guo W, Ding J, Meng LH. Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CA accompanied with pro-tumorigenic secretome. International Journal of Cancer. PMID 30671946 DOI: 10.1002/Ijc.32153 |
0.31 |
|
| 2019 |
Lev M, Ding J, Polat U, Levi D. Two eyes are not better than one with crowded targets Journal of Vision. 19: 66. DOI: 10.1167/19.10.66 |
0.471 |
|
| 2019 |
Ding J, Levi DM. A comprehensive depth perception model with filter/cross-correlation/filter (F-CC-F) structure Journal of Vision. 19: 263a. DOI: 10.1167/19.10.263A |
0.425 |
|
| 2019 |
Zhang T, Qu R, Chen C, Tong L, Feng F, Chen Y, Geng M, Ding K, Xie H, Ding J. Abstract 2210: Discovery of a novel third generation EGFR TKI and identification of its potential mechanism of resistance Cancer Research. 79: 2210-2210. DOI: 10.1158/1538-7445.Am2019-2210 |
0.329 |
|
| 2019 |
Wang Y, Zhang X, Ma Q, Zhang X, Yang C, Tan C, Hu L, Ding J, Meng L. Abstract A116: HRASG12S mutant mediates resistance to a PI3Kα inhibitor CYH33 in esophageal squamous cell carcinomas Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A116 |
0.352 |
|
| 2018 |
Wang X, Ai J, Liu H, Peng X, Chen H, Chen Y, Su Y, Shen A, Huang X, Ding J, Geng M. The secretome engages STAT3 to favor a cytokine-rich microenvironment in mediating acquired resistance to FGFR inhibitors. Molecular Cancer Therapeutics. PMID 30523050 DOI: 10.1158/1535-7163.Mct-18-0179 |
0.307 |
|
| 2018 |
Chen Z, Tong LJ, Tang BY, Liu HY, Wang X, Zhang T, Cao XW, Chen Y, Li HL, Qian XH, Xu YF, Xie H, Ding J. C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. Acta Pharmacologica Sinica. PMID 30487650 DOI: 10.1038/S41401-018-0191-7 |
0.34 |
|
| 2018 |
Lu X, Zhang T, Zhu SJ, Xun Q, Tong L, Hu X, Li Y, Chan S, Su Y, Sun Y, Chen Y, Ding J, Yun CH, Xie H, Ding K. Discovery of JND3229 as a New EGFR Mutant Inhibitor with In Vivo Monodrug Efficacy. Acs Medicinal Chemistry Letters. 9: 1123-1127. PMID 30429956 DOI: 10.1021/Acsmedchemlett.8B00373 |
0.319 |
|
| 2018 |
Zheng Q, Chen Z, Wan H, Tang S, Ye Y, Xu Y, Jiang L, Ding J, Geng M, Huang M, Huang Y. Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 30413349 DOI: 10.1016/J.Bmcl.2018.07.002 |
0.307 |
|
| 2018 |
Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, Wei R, Zheng XL, Liu Z, Zhang X, Yang H, Hao B, Shen YY, Su Y, Cong X, ... ... Ding J, et al. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Cell. PMID 30220457 DOI: 10.1016/J.Cell.2018.08.058 |
0.345 |
|
| 2018 |
Chen H, Song P, Diao Y, Hao Y, Dou D, Wang W, Fang X, Wang Y, Zhao Z, Ding J, Li H, Xie H, Xu Y. Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors. Medchemcomm. 9: 697-704. PMID 30108960 DOI: 10.1039/C8Md00019K |
0.347 |
|
| 2018 |
Liu YQ, Wang YN, Lu XY, Tong LJ, Li Y, Zhang T, Xun QJ, Feng F, Chen YZ, Su Y, Shen YY, Chen Y, Geng MY, Ding K, Li YL, ... ... Ding J, et al. Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R. Acta Pharmacologica Sinica. PMID 29968849 DOI: 10.1038/S41401-018-0056-0 |
0.327 |
|
| 2018 |
Sun J, Wang X, Tang B, Liu H, Zhang M, Wang Y, Ping F, Ding J, Shen A, Geng M. A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma. Theranostics. 8: 3256-3267. PMID 29930727 DOI: 10.7150/Thno.23964 |
0.324 |
|
| 2018 |
Hao Y, Lyu J, Qu R, Tong Y, Sun D, Feng F, Tong L, Yang T, Zhao Z, Zhu L, Ding J, Xu Y, Xie H, Li H. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. Journal of Medicinal Chemistry. PMID 29906114 DOI: 10.1021/Acs.Jmedchem.8B00346 |
0.309 |
|
| 2018 |
Yan Q, Chen Y, Tang B, Xiao Q, Qu R, Tong L, Liu J, Ding J, Chen Y, Ding N, Tan W, Xie H, Li Y. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation. European Journal of Medicinal Chemistry. 152: 298-306. PMID 29730192 DOI: 10.1016/J.Ejmech.2018.04.052 |
0.322 |
|
| 2018 |
Xue Y, Song P, Song Z, Wang A, Tong L, Geng MY, Ding J, Liu Q, Sun L, Xie H, Zhang A. Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton's Tyrosine Kinase (BTK) Inhibitors. Journal of Medicinal Chemistry. PMID 29715023 DOI: 10.1021/Acs.Jmedchem.8B00441 |
0.338 |
|
| 2018 |
Gambacorta C, Ding J, McKee SP, Levi DM. Both saccadic and manual responses in the amblyopic eye of strabismics are irreducibly delayed. Journal of Vision. 18: 20. PMID 29677336 DOI: 10.1167/18.3.20 |
0.739 |
|
| 2018 |
Liu XL, Ding J, Meng LH. Oncogene-induced senescence: a double edged sword in cancer. Acta Pharmacologica Sinica. PMID 29620049 DOI: 10.1038/Aps.2017.198 |
0.314 |
|
| 2018 |
Zha C, Deng W, Fu Y, Tang S, Lan X, Ye Y, Su Y, Jiang L, Chen Y, Huang Y, Ding J, Geng M, Huang M, Wan H. Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy. European Journal of Medicinal Chemistry. 148: 140-153. PMID 29459274 DOI: 10.1016/J.Ejmech.2018.02.022 |
0.363 |
|
| 2018 |
Leung ELH, Luo LX, Liu ZQ, Wong VKW, Lu LL, Xie Y, Zhang N, Qu YQ, Fan XX, Li Y, Huang M, Xiao DK, Huang J, Zhou YL, He JX, ... Ding J, et al. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. Cell Death & Disease. 9: 216. PMID 29440631 DOI: 10.1038/S41419-017-0065-9 |
0.328 |
|
| 2018 |
Zheng YD, Bai G, Tang C, Ke CQ, Yao S, Tong LJ, Feng F, Li Y, Ding J, Xie H, Ye Y. 7α,8α-Epoxynagilactones and their glucosides from the twigs of Podocarpus nagi: Isolation, structures, and cytotoxic activities. Fitoterapia. PMID 29355751 DOI: 10.1016/J.Fitote.2018.01.007 |
0.332 |
|
| 2018 |
Chen X, Huan X, Liu Q, Wang Y, He Q, Tan C, Chen Y, Ding J, Xu Y, Miao Z, Yang C. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors. European Journal of Medicinal Chemistry. 145: 389-403. PMID 29335205 DOI: 10.1016/J.Ejmech.2018.01.018 |
0.335 |
|
| 2018 |
Ding J, Levi D. Interocular interaction for second-order stimuli depends on interocular noise correlation and eye dominance Journal of Vision. 18: 958. DOI: 10.1167/18.10.958 |
0.467 |
|
| 2018 |
Xiang H, Wang X, Chen Y, Zhang X, Chen Y, Tan C, Wang Y, Ding J, Meng L, Yang C. Abstract LB-268: Discovery of clinical candidate methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-268 |
0.373 |
|
| 2018 |
Xie S, Wei F, Sun Y, Gao Y, Ding J, Chen Y. Abstract LB-259: EZH2 inhibitors abrogate upregulation of H3K27me3 by CDK9 inhibitors and potentiate its antitumor activity in DLBCL Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-259 |
0.362 |
|
| 2018 |
Zhang L, Zhang J, Qiao M, Yan X, Ding J, Chen F, An X, Tan W, Fu X, Yang W, Shi Q. Abstract B078: MiXenoTM: a fast and efficient humanized tumor model system for in vivo efficacy evaluation of novel immunotherapeutics Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B078 |
0.302 |
|
| 2017 |
Ai J, Chen Y, Peng X, Ji Y, Xi Y, Shen Y, Yang X, Su Y, Sun YM, Gao Y, Ma Y, Xiong B, Shen J, Ding J, Geng M. Preclinical evaluation of SCC244 (Glumetinib), a novel, potent and highly selective inhibitor of c-Met in MET-dependent cancer models. Molecular Cancer Therapeutics. PMID 29237805 DOI: 10.1158/1535-7163.Mct-17-0368 |
0.35 |
|
| 2017 |
Ding J, Levi DM. Binocular combination of luminance profiles. Journal of Vision. 17: 4. PMID 29098293 DOI: 10.1167/17.13.4 |
0.489 |
|
| 2017 |
Zheng Q, Tang S, Fu X, Chen Z, Ye Y, Lan X, Jiang L, Huang Y, Ding J, Geng M, Huang M, Wan H. Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 29079473 DOI: 10.1016/J.Bmcl.2017.10.029 |
0.311 |
|
| 2017 |
Fu Y, Tang S, Su Y, Lan X, Ye Y, Zha C, Li L, Cao J, Chen Y, Jiang L, Huang Y, Ding J, Geng M, Huang M, Wan H. Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 29074254 DOI: 10.1016/J.Bmcl.2017.09.050 |
0.36 |
|
| 2017 |
Chen L, Fu W, Feng C, Qu R, Tong L, Zheng L, Fang B, Qiu Y, Hu J, Cai Y, Feng J, Xie H, Ding J, Liu Z, Liang G. Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC. European Journal of Medicinal Chemistry. 140: 510-527. PMID 28987609 DOI: 10.1016/J.Ejmech.2017.08.061 |
0.324 |
|
| 2017 |
Xie Q, Chen H, Ai J, Gao YL, Geng MY, Ding J, Chen Y. Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer. Acta Pharmacologica Sinica. PMID 28795691 DOI: 10.1038/Aps.2017.107 |
0.319 |
|
| 2017 |
Chen WH, Song SS, Qi MH, Huan XJ, Wang YQ, Jiang H, Ding J, Ren GB, Miao ZH, Li J. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy. Acta Pharmacologica Sinica. PMID 28770827 DOI: 10.1038/Aps.2017.104 |
0.351 |
|
| 2017 |
Dai XY, Yan J, Fu X, Pan Q, Sun D, Xu Y, Wang J, Nie L, Tong LJ, Shen A, Zheng M, Huang M, Tan M, Liu H, Huang X, ... Ding J, et al. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28710312 DOI: 10.1158/1078-0432.Ccr-17-0242 |
0.325 |
|
| 2017 |
Chen W, Guo N, Qi M, Dai H, Hong M, Guan L, Huan X, Song S, He J, Wang Y, Xi Y, Yang X, Shen Y, Su Y, Sun Y, ... ... Ding J, et al. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy. European Journal of Medicinal Chemistry. 138: 514-531. PMID 28692916 DOI: 10.1016/J.Ejmech.2017.06.053 |
0.354 |
|
| 2017 |
Sun D, Liu H, Dai X, Zheng X, Yan J, Wei R, Fu X, Huang M, Shen A, Huang X, Ding J, Geng M. Aspirin Disrupts the mTOR-Raptor Complex and Potentiates the Anti-Cancer Activities of Sorafenib via mTORC1 Inhibition. Cancer Letters. PMID 28687354 DOI: 10.1016/J.Canlet.2017.06.029 |
0.326 |
|
| 2017 |
Hao Y, Lyu J, Qu R, Sun D, Zhao Z, Chen Z, Ding J, Xie H, Xu Y, Li H. Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors. Scientific Reports. 7: 3830. PMID 28630494 DOI: 10.1038/S41598-017-04184-9 |
0.334 |
|
| 2017 |
Li X, Tang S, Wang QQ, Leung EL, Jin H, Huang Y, Liu J, Geng M, Huang M, Yuan S, Yao XJ, Ding J. Identification of Epigallocatechin-3- Gallate as an Inhibitor of Phosphoglycerate Mutase 1. Frontiers in Pharmacology. 8: 325. PMID 28611670 DOI: 10.3389/Fphar.2017.00325 |
0.352 |
|
| 2017 |
Wang GM, Wang X, Zhu JM, Guo BB, Yang Z, Xu ZJ, Li B, Wang HY, Meng LH, Zhu WL, Ding J. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf(V600E) inhibitors. Acta Pharmacologica Sinica. PMID 28414204 DOI: 10.1038/Aps.2016.173 |
0.306 |
|
| 2017 |
Yang ZM, Liao XM, Chen Y, Shen YY, Yang XY, Su Y, Sun YM, Gao YL, Ding J, Zhang A, He JX, Miao ZH. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors. Acta Pharmacologica Sinica. PMID 28414200 DOI: 10.1038/Aps.2017.8 |
0.322 |
|
| 2017 |
Xu YC, Wang X, Chen Y, Chen SM, Yang XY, Sun YM, Geng MY, Ding J, Meng LH. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer. Theranostics. 7: 974-986. PMID 28382169 DOI: 10.7150/Thno.17830 |
0.328 |
|
| 2017 |
Yue X, Ai J, Xu Y, Chen Y, Huang M, Yang X, Hu B, Zhang H, He C, Yang X, Tang W, Peng X, Dong L, Wang H, Fan J, ... Ding J, et al. Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. Hepatology (Baltimore, Md.). PMID 28073159 DOI: 10.1002/Hep.29036 |
0.304 |
|
| 2017 |
Ding J, Yehezkel O, Sterkin A, Polat U, Levi D. Interocular enhancement revealed in binocular combination Journal of Vision. 17: 154. DOI: 10.1167/17.10.154 |
0.482 |
|
| 2016 |
Yehezkel O, Ding J, Sterkin A, Polat U, Levi DM. Binocular combination of stimulus orientation. Royal Society Open Science. 3: 160534. PMID 28018641 DOI: 10.1098/Rsos.160534 |
0.486 |
|
| 2016 |
He JX, Wang M, Huan XJ, Chen CH, Song SS, Wang YQ, Liao XM, Tan C, He Q, Tong LJ, Wang YT, Li XH, Su Y, Shen YY, Sun YM, ... ... Ding J, et al. Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. Oncotarget. PMID 27926532 DOI: 10.18632/Oncotarget.13749 |
0.344 |
|
| 2016 |
Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, ... ... Ding J, et al. Poly(ADP-ribose)polymerase (PARP) Inhibition and Anticancer Activity of Simmiparib, a New Inhibitor Undergoing Clinical Trials. Cancer Letters. PMID 27847302 DOI: 10.1016/J.Canlet.2016.11.010 |
0.351 |
|
| 2016 |
Wei M, Zhang X, Wang X, Song Z, Ding J, Meng LH, Zhang A. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors. European Journal of Medicinal Chemistry. 125: 1156-1171. PMID 27846451 DOI: 10.1016/J.Ejmech.2016.11.014 |
0.339 |
|
| 2016 |
Zeng H, Qu J, Jin N, Xu J, Lin C, Chen Y, Yang X, He X, Tang S, Lan X, Yang X, Chen Z, Huang M, Ding J, Geng M. Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer. Cancer Cell. 30: 459-473. PMID 27622335 DOI: 10.1016/J.Ccell.2016.08.001 |
0.316 |
|
| 2016 |
Wang YQ, Shen AJ, Sun JY, Wang X, Liu HC, Zhang MM, Chen DQ, Xiong B, Shen JK, Geng MY, Zheng M, Ding J. Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells. Acta Pharmacologica Sinica. PMID 27616574 DOI: 10.1038/Aps.2016.85 |
0.308 |
|
| 2016 |
Xie S, Jiang H, Zhai XW, Wei F, Wang SD, Ding J, Chen Y. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacologica Sinica. PMID 27569395 DOI: 10.1038/Aps.2016.49 |
0.331 |
|
| 2016 |
Liu H, Ai J, Shen A, Chen Y, Wang X, Peng X, Chen H, Shen Y, Huang M, Ding J, Geng M. c-Myc alteration determines the therapeutic response to FGFR inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27401245 DOI: 10.1158/1078-0432.Ccr-15-2448 |
0.316 |
|
| 2016 |
Hao Y, Wang X, Zhang T, Sun D, Tong Y, Xu Y, Chen H, Tong L, Zhu L, Zhao Z, Chen Z, Ding J, Xie H, Xu Y, Li H. Discovery and Structural Optimization of N5-Substituted 6,7-dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors Against L858R/T790M Resistance Mutation. Journal of Medicinal Chemistry. PMID 27396610 DOI: 10.1021/Acs.Jmedchem.6B00403 |
0.329 |
|
| 2016 |
Vedamurthy I, Knill DC, Huang SJ, Yung A, Ding J, Kwon OS, Bavelier D, Levi DM. Recovering stereo vision by squashing virtual bugs in a virtual reality environment. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 371. PMID 27269607 DOI: 10.1098/Rstb.2015.0264 |
0.455 |
|
| 2016 |
Wang Y, Zhan Z, Jiang X, Peng X, Shen Y, Chen F, Ji Y, Liu W, Shi Y, Duan W, Ding J, Ai J, Geng M. Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities. Oncotarget. PMID 27191264 DOI: 10.18632/Oncotarget.9349 |
0.335 |
|
| 2016 |
Xiao Q, Qu R, Gao D, Yan Q, Tong L, Zhang W, Ding J, Xie H, Li Y. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors. Bioorganic & Medicinal Chemistry. PMID 27131639 DOI: 10.1016/J.Bmc.2016.04.032 |
0.341 |
|
| 2016 |
Li L, Liu F, Jin N, Tang S, Chen Z, Yang X, Ding J, Geng M, Jiang L, Huang M, Cao J. Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2). Bioorganic & Medicinal Chemistry Letters. PMID 27106711 DOI: 10.1016/J.Bmcl.2016.04.029 |
0.311 |
|
| 2016 |
Ding J, Levi DM. Binocular contrast discrimination needs monocular multiplicative noise. Journal of Vision. 16: 12. PMID 26982370 DOI: 10.1167/16.5.12 |
0.482 |
|
| 2016 |
Li MY, Lv YC, Tong LJ, Peng T, Qu R, Zhang T, Sun YM, Chen Y, Wei LX, Geng MY, Duan WH, Xie H, Ding J. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo. Acta Pharmacologica Sinica. PMID 26806300 DOI: 10.1038/Aps.2015.117 |
0.317 |
|
| 2016 |
Ding J, Levi D. Disparity thresholds Dmin and Dmax both depend on interocular contrast difference Journal of Vision. 16: 830. DOI: 10.1167/16.12.830 |
0.459 |
|
| 2016 |
Levi D, Vedamurthy I, Knill D, Ding J, Kwon O, Bavelier D. Recovering stereo vision by squashing virtual bugs in a VR environment. Journal of Vision. 16: 201. DOI: 10.1167/16.12.201 |
0.431 |
|
| 2016 |
Gao G, Li M, Lv Y, Cao S, Tong L, Wei L, Ding J, Xie H, Duan W. Design, synthesis and biological evaluation of biphenylurea derivatives as VEGFR-2 kinase inhibitors (II) Chinese Chemical Letters. 27: 200-204. DOI: 10.1016/J.Cclet.2015.10.004 |
0.338 |
|
| 2015 |
Yan W, Huang Z, Wang Z, Cao S, Tong L, Zhang T, Wang C, Zhou L, Ding J, Luo C, Zhou J, Xie H, Duan W. Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis and Biological Evaluation. Chemical Biology & Drug Design. PMID 26669707 DOI: 10.1111/Cbdd.12703 |
0.321 |
|
| 2015 |
Fan XX, Yao XJ, Xu SW, Wong VK, He JX, Ding J, Xue WW, Mujtaba T, Michelangeli F, Huang M, Huang J, Xiao DK, Jiang ZB, Zhou YL, Kin-Ting Kam R, et al. (Z)3,4,5,4'-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level. Scientific Reports. 5: 16348. PMID 26542098 DOI: 10.1038/Srep16348 |
0.315 |
|
| 2015 |
Shen A, Wang L, Huang M, Sun J, Chen Y, Shen YY, Yang X, Wang X, Ding J, Geng M. c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers. Cancer Research. PMID 26483207 DOI: 10.1158/0008-5472.Can-14-2743 |
0.302 |
|
| 2015 |
Jiang X, Zhou J, Ai J, Song Z, Peng X, Xing L, Xi Y, Guo J, Yao Q, Ding J, Geng M, Zhang A. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: Design, synthesis, and structure-activity relationship study. European Journal of Medicinal Chemistry. 105: 39-56. PMID 26476749 DOI: 10.1016/J.Ejmech.2015.10.005 |
0.321 |
|
| 2015 |
Yu Q, Ding J. Precision cancer medicine: where to target? Acta Pharmacologica Sinica. PMID 26388154 DOI: 10.1038/Aps.2015.93 |
0.328 |
|
| 2015 |
Ding J, Levi D. Interocular contrast gain control plus monocular luminance gain control can explain binocular luminance summation. Journal of Vision. 15: 263. PMID 26325951 DOI: 10.1167/15.12.263 |
0.46 |
|
| 2015 |
Chan S, Han K, Qu R, Tong L, Li Y, Zhang Z, Cheng H, Lu X, Patterson A, Smaill J, Ren X, Ding J, Xie H, Ding K. 2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L858R/T790M). Bioorganic & Medicinal Chemistry Letters. PMID 26259806 DOI: 10.1016/J.Bmcl.2015.07.089 |
0.352 |
|
| 2015 |
Guo XB, Chen XJ, Tong LJ, Peng X, Huang M, Liu HC, Liu H, Ding J. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro. Acta Pharmacologica Sinica. PMID 26027659 DOI: 10.1038/Aps.2015.25 |
0.347 |
|
| 2015 |
Yi JM, Zhang XF, Huan XJ, Song SS, Wang W, Tian QT, Sun YM, Chen Y, Ding J, Wang YQ, Yang CH, Miao ZH. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition. Oncotarget. 6: 8960-73. PMID 25840421 DOI: 10.18632/Oncotarget.3264 |
0.34 |
|
| 2015 |
Ma Y, Sun G, Chen D, Peng X, Chen YL, Su Y, Ji Y, Liang J, Wang X, Chen L, Ding J, Xiong B, Ai J, Geng M, Shen J. Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors. Journal of Medicinal Chemistry. 58: 2513-29. PMID 25668160 DOI: 10.1021/Jm502018Y |
0.335 |
|
| 2015 |
Song Z, Yang Y, Liu Z, Peng X, Guo J, Yang X, Wu K, Ai J, Ding J, Geng M, Zhang A. Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases. Journal of Medicinal Chemistry. 58: 197-211. PMID 24785465 DOI: 10.1021/Jm5005144 |
0.332 |
|
| 2015 |
Xu T, Peng T, Ren X, Zhang L, Yu L, Luo J, Zhang Z, Tu Z, Tong L, Huang Z, Lu X, Geng M, Xie H, Ding J, Ding K. C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant Medchemcomm. 6: 1693-1697. DOI: 10.1039/C5Md00208G |
0.341 |
|
| 2015 |
Lv Y, Li M, Cao S, Tong L, Peng T, Wei L, Xie H, Ding J, Duan W. Discovery of anilinopyrimidine-based naphthamide derivatives as potent VEGFR-2 inhibitors Medchemcomm. 6: 1375-1380. DOI: 10.1039/C5Md00191A |
0.321 |
|
| 2015 |
Gao GR, Li MY, Tong LJ, Wei LX, Ding J, Xie H, Duan WH. Design, synthesis and biological evaluation of O-linked indoles as VEGFR-2 kinase inhibitors (I) Chinese Chemical Letters. DOI: 10.1016/J.Cclet.2015.07.016 |
0.329 |
|
| 2015 |
Gao G, Liu J, Mei D, Ding J, Meng L, Duan W. Design, synthesis and biological evaluation of acylhydrazone derivatives as PI3K inhibitors Chinese Chemical Letters. 26: 118-120. DOI: 10.1016/J.Cclet.2014.10.016 |
0.333 |
|
| 2014 |
He PX, Zhang J, Che YS, He QJ, Chen Y, Ding J. G226, a new epipolythiodioxopiperazine derivative, triggers DNA damage and apoptosis in human cancer cells in vitro via ROS generation. Acta Pharmacologica Sinica. 35: 1546-55. PMID 25468822 DOI: 10.1038/Aps.2014.105 |
0.32 |
|
| 2014 |
Lam F, Abbas AY, Shao H, Teo T, Adams J, Li P, Bradshaw TD, Fischer PM, Walsby E, Pepper C, Chen Y, Ding J, Wang S. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget. 5: 7691-704. PMID 25277198 DOI: 10.18632/Oncotarget.2296 |
0.337 |
|
| 2014 |
Liu Z, Yue X, Song Z, Peng X, Guo J, Ji Y, Cheng Z, Ding J, Ai J, Geng M, Zhang A. Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors. European Journal of Medicinal Chemistry. 86: 438-48. PMID 25200979 DOI: 10.1016/J.Ejmech.2014.09.003 |
0.324 |
|
| 2014 |
Tan S, Han K, Li Q, Tong L, Yang Y, Chen Z, Xie H, Ding J, Qian X, Xu Y. Novel metal complexes of naphthalimide-cyclam conjugates as potential multi-target receptor tyrosine kinase (RTK) inhibitors: synthesis and biological evaluation. European Journal of Medicinal Chemistry. 85: 207-14. PMID 25084146 DOI: 10.1016/J.Ejmech.2014.07.068 |
0.332 |
|
| 2014 |
He PX, Che YS, He QJ, Chen Y, Ding J. G226, a novel epipolythiodioxopiperazine derivative, induces autophagy and caspase-dependent apoptosis in human breast cancer cells in vitro. Acta Pharmacologica Sinica. 35: 1055-64. PMID 25066322 DOI: 10.1038/Aps.2014.47 |
0.304 |
|
| 2014 |
Liu LP, Han K, Chen W, Zhang YY, Tong LJ, Peng T, Xie H, Ding J, Wang HB. Topoisomerase II inhibitors from the roots of Stellera chamaejasme L. Bioorganic & Medicinal Chemistry. 22: 4198-203. PMID 24931277 DOI: 10.1016/J.Bmc.2014.05.042 |
0.326 |
|
| 2014 |
Lv Y, Li M, Liu T, Tong L, Peng T, Wei L, Ding J, Xie H, Duan W. Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase Inhibitors. Acs Medicinal Chemistry Letters. 5: 592-7. PMID 24900886 DOI: 10.1021/Ml5000417 |
0.347 |
|
| 2014 |
Wang L, Ai J, Shen Y, Zhang H, Peng X, Huang M, Zhang A, Ding J, Geng M. SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo. Cancer Letters. 351: 143-50. PMID 24880078 DOI: 10.1016/J.Canlet.2014.05.012 |
0.334 |
|
| 2014 |
Peng T, Wu JR, Tong LJ, Li MY, Chen F, Leng YX, Qu R, Han K, Su Y, Chen Y, Duan WH, Xie H, Ding J. Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin. Acta Pharmacologica Sinica. 35: 916-28. PMID 24858311 DOI: 10.1038/Aps.2014.33 |
0.324 |
|
| 2014 |
Zhang HT, Wang L, Ai J, Chen Y, He CX, Ji YC, Huang M, Yang JY, Zhang A, Ding J, Geng MY. SOMG-833, a novel selective c-MET inhibitor, blocks c-MET-dependent neoplastic effects and exerts antitumor activity. The Journal of Pharmacology and Experimental Therapeutics. 350: 36-45. PMID 24741075 DOI: 10.1124/Jpet.114.214817 |
0.345 |
|
| 2014 |
Ji X, Peng T, Zhang X, Li J, Yang W, Tong L, Qu R, Jiang H, Ding J, Xie H, Liu H. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors. Bioorganic & Medicinal Chemistry. 22: 2366-78. PMID 24565969 DOI: 10.1016/J.Bmc.2014.01.035 |
0.315 |
|
| 2014 |
Ding J, Levi DM. Rebalancing binocular vision in amblyopia. Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists). 34: 199-213. PMID 24417338 DOI: 10.1111/Opo.12115 |
0.481 |
|
| 2014 |
Liu JL, Gao GR, Zhang X, Cao SF, Guo CL, Wang X, Tong LJ, Ding J, Duan WH, Meng LH. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R). The Journal of Pharmacology and Experimental Therapeutics. 348: 432-41. PMID 24361696 DOI: 10.1124/Jpet.113.210724 |
0.374 |
|
| 2014 |
He CX, Ai J, Xing WQ, Chen Y, Zhang HT, Huang M, Hu YH, Ding J, Geng MY. Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacologica Sinica. 35: 89-97. PMID 24241352 DOI: 10.1038/Aps.2013.125 |
0.325 |
|
| 2014 |
Ding J, Levi D. Binocular asymmetry in amblyopia F1000research. 14: 957-957. DOI: 10.7490/F1000Research.1095904.1 |
0.461 |
|
| 2013 |
Zhang X, Peng T, Ji X, Li J, Tong L, Li Z, Yang W, Xu Y, Li M, Ding J, Jiang H, Xie H, Liu H. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. Bioorganic & Medicinal Chemistry. 21: 7988-98. PMID 24183742 DOI: 10.1016/J.Bmc.2013.09.049 |
0.331 |
|
| 2013 |
Wang X, Li J, Yang Y, Ding J, Meng L. A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth. Acta Pharmacologica Sinica. 34: 1201-1207. PMID 23892273 DOI: 10.1038/Aps.2013.81 |
0.354 |
|
| 2013 |
Wang X, Chen Z, Tong L, Tan S, Zhou W, Peng T, Han K, Ding J, Xie H, Xu Y. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs). European Journal of Medicinal Chemistry. 65: 477-86. PMID 23770449 DOI: 10.1016/J.Ejmech.2013.05.002 |
0.342 |
|
| 2013 |
Mao Y, Zhu W, Kong X, Wang Z, Xie H, Ding J, Terrett NK, Shen J, Shen J. Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry. 21: 3090-104. PMID 23602524 DOI: 10.1016/J.Bmc.2013.03.053 |
0.328 |
|
| 2013 |
Ding J, Klein SA, Levi DM. Binocular combination in abnormal binocular vision. Journal of Vision. 13: 14. PMID 23397039 DOI: 10.1167/13.2.14 |
0.494 |
|
| 2013 |
Ding J, Klein SA, Levi DM. Binocular combination of phase and contrast explained by a gain-control and gain-enhancement model. Journal of Vision. 13: 13. PMID 23397038 DOI: 10.1167/13.2.13 |
0.472 |
|
| 2013 |
Klein S, Ding J, Levi D. Controversies in dealing with visual noise F1000research. 4. DOI: 10.7490/F1000Research.1094306.1 |
0.437 |
|
| 2013 |
Chen S, Guo C, Ding J, Meng L. Abstract 909: Hsp90 inhibitor AUY922 abrogates mTOR inhibitor AZD8055-induced up-regulation of HER2/HER3 and potentiates antiproliferative activity in human breast cancer cells. Cancer Research. 73: 909-909. DOI: 10.1158/1538-7445.Am2013-909 |
0.353 |
|
| 2013 |
Xu L, Feng J, Li J, Zhu J, Song S, Tong L, Chen Y, Lian F, Lin D, Ding J, Miao Z. Abstract 878: Tanshinone-1 kills multidrug resistant tumor cells via reducing phospho-705-Stat3, potentiated by inhibiting secondary activation of signaling networks. Cancer Research. 73: 878-878. DOI: 10.1158/1538-7445.Am2013-878 |
0.356 |
|
| 2013 |
Wang X, Li B, Ding L, Liang C, Ding J, Meng L. Abstract 3262: Targeting PI3K-coupled MEK/ERK pathway for therapy in pediatric B-cell acute lymphocytic leukemia. Cancer Research. 73: 3262-3262. DOI: 10.1158/1538-7445.Am2013-3262 |
0.325 |
|
| 2013 |
Song Z, Ai J, Liu Z, Peng X, Chen Y, Ding J, Geng M, Zhang A. Abstract B99: Discovery of 2,4-diarylaminopyrimidine SOMCL-12-81 as a potent inhibitor targeting both wild and mutant ALK kinases. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B99 |
0.361 |
|
| 2013 |
Ai J, Zhan Z, Wang Y, Chen F, Peng X, Chen Y, Ji Y, Ding J, Geng M, Duan W. Abstract B285: A novel, potent, highly selective inhibitor of c-Met kinase, Simm559, inhibits c-Met-dependent neoplastic phenotypes in vitro and in vivo. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B285 |
0.344 |
|
| 2012 |
Zeng LF, Wang Y, Kazemi R, Xu S, Xu ZL, Sanchez TW, Yang LM, Debnath B, Odde S, Xie H, Zheng YT, Ding J, Neamati N, Long YQ. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. Journal of Medicinal Chemistry. 55: 9492-509. PMID 23098137 DOI: 10.1021/Jm300667V |
0.335 |
|
| 2012 |
Miao Z, Feng J, Ding J. Newly discovered angiogenesis inhibitors and their mechanisms of action Acta Pharmacologica Sinica. 33: 1103-1111. PMID 22922347 DOI: 10.1038/Aps.2012.97 |
0.339 |
|
| 2012 |
Chang S, Zhang L, Xu S, Luo J, Lu X, Zhang Z, Xu T, Liu Y, Tu Z, Xu Y, Ren X, Geng M, Ding J, Pei D, Ding K. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant. Journal of Medicinal Chemistry. 55: 2711-23. PMID 22339342 DOI: 10.1021/Jm201591K |
0.349 |
|
| 2012 |
Zhou Y, Chen Y, Tong L, Xie H, Wen W, Zhang J, Xi Y, Shen Y, Geng M, Wang Y, Jiang H, Luo C, Lin L, Ding J. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. Journal of Cellular and Molecular Medicine. 16: 2321-30. PMID 22304225 DOI: 10.1111/J.1582-4934.2012.01541.X |
0.307 |
|
| 2012 |
Wang J, Wang X, Chen Y, Chen S, Chen G, Tong L, Meng L, Xie Y, Ding J, Yang C. Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors. Bioorganic & Medicinal Chemistry Letters. 22: 339-42. PMID 22130133 DOI: 10.1016/J.Bmcl.2011.11.003 |
0.341 |
|
| 2012 |
Ding J, Klein S, Gong C, Levi D. Noise alters binocular combination F1000research. 12: 48-48. DOI: 10.7490/F1000Research.1090383.1 |
0.442 |
|
| 2011 |
Dong SH, Liu HB, Xu CH, Ding J, Yue JM. Constituents of Trigonostemon heterophyllus. Journal of Natural Products. 74: 2576-81. PMID 22122667 DOI: 10.1021/Np200772N |
0.308 |
|
| 2011 |
Ding J, Levi DM. Recovery of stereopsis through perceptual learning in human adults with abnormal binocular vision. Proceedings of the National Academy of Sciences of the United States of America. 108: E733-41. PMID 21896742 DOI: 10.1073/Pnas.1105183108 |
0.475 |
|
| 2011 |
Xie H, Lin L, Tong L, Jiang Y, Zheng M, Chen Z, Jiang X, Zhang X, Ren X, Qu W, Yang Y, Wan H, Chen Y, Zuo J, Jiang H, ... ... Ding J, et al. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. Plos One. 6: e21487. PMID 21789172 DOI: 10.1371/Journal.Pone.0021487 |
0.361 |
|
| 2011 |
Chen Z, Wang X, Zhu W, Cao X, Tong L, Li H, Xie H, Xu Y, Tan S, Kuang D, Ding J, Qian X. Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity. Journal of Medicinal Chemistry. 54: 3732-45. PMID 21517068 DOI: 10.1021/Jm200258T |
0.36 |
|
| 2011 |
Ding J, Levi D. The spatial limits of recovered stereopsis in strabismic/amblyopic adults F1000research. 2. DOI: 10.7490/F1000Research.1089361.1 |
0.432 |
|
| 2010 |
Ma JG, Huang H, Chen SM, Chen Y, Xin XL, Lin LP, Ding J, Liu H, Meng LH. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo. Breast Cancer Research and Treatment. 130: 85-96. PMID 21181437 DOI: 10.1007/S10549-010-1302-4 |
0.343 |
|
| 2010 |
Huang H, Ma J, Shi J, Meng L, Jiang H, Ding J, Liu H. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase. Bioorganic & Medicinal Chemistry. 18: 4615-4624. PMID 20570525 DOI: 10.1016/J.Bmc.2010.05.032 |
0.337 |
|
| 2010 |
Huang H, Chen Q, Ku X, Meng L, Lin L, Wang X, Zhu C, Wang Y, Chen Z, Li M, Jiang H, Chen K, Ding J, Liu H. A Series of α-Heterocyclic Carboxaldehyde Thiosemicarbazones Inhibit Topoisomerase IIα Catalytic Activity Journal of Medicinal Chemistry. 53: 3048-3064. PMID 20353152 DOI: 10.1021/Jm9014394 |
0.344 |
|
| 2010 |
Ding J, Klein S, Levi D. Binocular combinaiton in amblyopic vision F1000research. 3: 274-274. DOI: 10.7490/F1000Research.1092638.1 |
0.465 |
|
| 2010 |
Ding J, Srinivasan R, Sperling G. Flicker elicits eeg responses in two distinct cortical networks depending on attention and flicker frequency Journal of Vision. 6: 515-515. DOI: 10.1167/6.6.515 |
0.509 |
|
| 2010 |
Ding J, Levi D. Recovery of stereopsis in human adults with strabismus through perceptual learning Journal of Vision. 10: 1124-1124. DOI: 10.1167/10.7.1124 |
0.431 |
|
| 2009 |
Sun QM, Miao ZH, Lin LP, Gui M, Zhu CH, Xie H, Duan WH, Ding J. BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities. Cancer Biology & Therapy. 8: 1640-7. PMID 19625781 DOI: 10.4161/Cbt.8.17.9205 |
0.33 |
|
| 2009 |
Li Q, Liu H, Xin X, Pan Q, Wang L, Zhang J, Chen Q, Geng M, Ding J. Marine-derived oligosaccharide sulfate (JG3) suppresses heparanase-driven cell adhesion events in heparanase over-expressing CHO-K1 cells. Acta Pharmacologica Sinica. 30: 1033-1038. PMID 19543297 DOI: 10.1038/Aps.2009.97 |
0.303 |
|
| 2009 |
Huang H, Jia Q, Ma J, Qin G, Chen Y, Xi Y, Lin L, Zhu W, Ding J, Jiang H, Liu H. Discovering novel quercetin-3-O-amino acid-esters as a new class of Src tyrosine kinase inhibitors. European Journal of Medicinal Chemistry. 44: 1982-8. PMID 19041163 DOI: 10.1016/J.Ejmech.2008.09.051 |
0.308 |
|
| 2009 |
Xie H, Lin L, Tong L, Jiang Y, Wang Y, Zhang X, Geng M, Guo J, Ding J. Abstract C50: AST‐6, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, inhibits tumor growth both in vitro and in vivo Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C50 |
0.373 |
|
| 2008 |
Ma J, Xin X, Meng L, Tong L, Lin L, Geng M, Ding J. The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo. Plos One. 3. PMID 19020661 DOI: 10.1371/Journal.Pone.0003774 |
0.352 |
|
| 2008 |
Lin LG, Xie H, Li HL, Tong LJ, Tang CP, Ke CQ, Liu QF, Lin LP, Geng MY, Jiang H, Zhao WM, Ding J, Ye Y. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening Journal of Medicinal Chemistry. 51: 4419-4429. PMID 18610999 DOI: 10.1021/Jm701501X |
0.346 |
|
| 2008 |
Lu J, Meng L, Cai Y, Chen Q, Tong L, Lin L, Ding J. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biology & Therapy. 7: 1017-1023. PMID 18414062 DOI: 10.4161/Cbt.7.7.6035 |
0.304 |
|
| 2008 |
Yang S, Cai Y, Zhang B, Tong L, Xie H, Wu Y, Lin L, Ding J, Yue J. Structural Modification of an Angiogenesis Inhibitor Discovered from Traditional Chinese Medicine and a Structure–Activity Relationship Study Journal of Medicinal Chemistry. 51: 77-85. PMID 18078313 DOI: 10.1021/Jm070906G |
0.36 |
|
| 2008 |
Shen Y, Zhang Y, Zhang Z, Miao Z, Ding J. hTERT-targeted RNA interference inhibits tumorigenicity and motility of HCT116 cells Cancer Biology & Therapy. 7: 228-236. PMID 18059183 DOI: 10.4161/Cbt.7.2.5259 |
0.309 |
|
| 2007 |
Meng L, Ding J. Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation Acta Pharmacologica Sinica. 28: 1460-1465. PMID 17723179 DOI: 10.1111/J.1745-7254.2007.00698.X |
0.317 |
|
| 2007 |
Srinivasan R, Winter WR, Ding J, Nunez PL. EEG and MEG coherence: measures of functional connectivity at distinct spatial scales of neocortical dynamics. Journal of Neuroscience Methods. 166: 41-52. PMID 17698205 DOI: 10.1016/J.Jneumeth.2007.06.026 |
0.678 |
|
| 2007 |
Winter WR, Nunez PL, Ding J, Srinivasan R. Comparison of the effect of volume conduction on EEG coherence with the effect of field spread on MEG coherence. Statistics in Medicine. 26: 3946-57. PMID 17607723 DOI: 10.1002/Sim.2978 |
0.679 |
|
| 2007 |
Tian F, Zhu CH, Zhang XW, Xie X, Xin XL, Yi YH, Lin LP, Geng MY, Ding J. Philinopside E, a new sulfated saponin from sea cucumber, blocks the interaction between kinase insert domain-containing receptor (KDR) and alphavbeta3 integrin via binding to the extracellular domain of KDR. Molecular Pharmacology. 72: 545-52. PMID 17565003 DOI: 10.1124/Mol.107.036350 |
0.301 |
|
| 2007 |
Zhang ZH, Chen Y, Zhao HJ, Xie CY, Ding J, Hou YT. Silencing of heparanase by siRNA inhibits tumor metastasis and angiogenesis of human breast cancer in vitro and in vivo. Cancer Biology & Therapy. 6: 587-95. PMID 17457040 DOI: 10.4161/Cbt.6.4.3888 |
0.32 |
|
| 2007 |
Li W, Shao Y, Hu L, Zhang X, Chen Y, Tong L, Li C, Shen X, Ding J. BM6, a new semi-synthetic vinca alkaloid, exhibits its potent in vivo anti-tumor activities via its high binding affinity for tubulin and improved pharmacokinetic profiles. Cancer Biology & Therapy. 6: 787-94. PMID 17387272 DOI: 10.4161/Cbt.6.5.4006 |
0.325 |
|
| 2007 |
Wu M, Sun Q, Yang C, Chen D, Ding J, Chen Y, Lin L, Xie Y. Synthesis and activity of Combretastatin A-4 analogues: 1,2,3-thiadiazoles as potent antitumor agents. Bioorganic & Medicinal Chemistry Letters. 17: 869-73. PMID 17174089 DOI: 10.1016/J.Bmcl.2006.11.060 |
0.306 |
|
| 2006 |
Zheng M, Xu C, Ma J, Sun Y, Du F, Liu H, Lin L, Li C, Ding J, Chen K, Jiang H. Synthesis and antitumor evaluation of a novel series of triaminotriazine derivatives. Bioorganic & Medicinal Chemistry. 15: 1815-27. PMID 17157510 DOI: 10.1016/J.Bmc.2006.11.028 |
0.315 |
|
| 2006 |
Zhao H, Liu H, Chen Y, Xin X, Li J, Hou Y, Zhang Z, Zhang X, Xie C, Geng M, Ding J. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Research. 66: 8779-87. PMID 16951194 DOI: 10.1158/0008-5472.Can-06-1382 |
0.347 |
|
| 2006 |
Zhong L, Guo XN, Zhang XH, Sun QM, Tong LJ, Wu ZX, Luo XM, Jiang HL, Nan FJ, Zhang XW, Lin LP, Ding J. TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRbeta. Cancer Biology & Therapy. 5: 323-30. PMID 16575201 DOI: 10.4161/Cbt.5.3.2543 |
0.316 |
|
| 2006 |
Ding J, Sperling G, Srinivasan R. Attentional modulation of SSVEP power depends on the network tagged by the flicker frequency. Cerebral Cortex (New York, N.Y. : 1991). 16: 1016-29. PMID 16221931 DOI: 10.1093/Cercor/Bhj044 |
0.526 |
|
| 2006 |
Tian F, Zhang X, Tong Y, Yi Y, Zhang S, Li L, Sun P, Lin L, Ding J. PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo. Cancer Biology & Therapy. 4: 874-82. PMID 16082187 DOI: 10.4161/Cbt.4.8.1917 |
0.322 |
|
| 2006 |
Yi YH, Xu QZ, Li L, Zhang SL, Wu HM, Ding J, Tong YG, Tan WF, Li MH, Tian F, Wu JH, Liaw CC, Bastow KF, Lee KH. Philinopsides A and B, two new sulfated triterpene glycosides from the sea cucumber Pentacta quadrangularis Helvetica Chimica Acta. 89: 54-63. DOI: 10.1002/Hlca.200690012 |
0.301 |
|
| 2005 |
Guo X, Zhong L, Tan J, Li J, Luo X, Jiang H, Nan F, Lin L, Zhang X, Ding J. In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with anti-tumor and anti-angiogenic effects. Cancer Biology & Therapy. 4: 1125-1132. PMID 16096368 DOI: 10.4161/Cbt.4.10.2024 |
0.331 |
|
| 2005 |
Jin Y, Li H, Lin L, Tan J, Ding J, Luo X, Long Y. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors. Bioorganic & Medicinal Chemistry. 13: 5613-5622. PMID 15993078 DOI: 10.1016/J.Bmc.2005.05.045 |
0.363 |
|
| 2005 |
Lu DY, Huang M, Xu CH, Yang WY, Hu CX, Lin LP, Tong LJ, Li MH, Lu W, Zhang XW, Ding J. Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. Bmc Pharmacology. 5: 11. PMID 15963241 DOI: 10.1186/1471-2210-5-11 |
0.304 |
|
| 2005 |
Tong Y, Zhang X, Tian F, Yi Y, Xu Q, Li L, Tong L, Lin L, Ding J. Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects. International Journal of Cancer. 114: 843-53. PMID 15645493 DOI: 10.1002/Ijc.20804 |
0.322 |
|
| 2005 |
Gao H, Huang M, Sun J, Shen H, Lu W, Zhang X, Li C, Ding J, Cai J. Small 9-Alkyl Derivatives of 10-Hydroxycamptothecin with Potent Antitumor Activity in Vitro and in Vivo Journal of Medicinal Chemistry. 0-0. DOI: 10.1021/Jm049307P |
0.303 |
|
| 2004 |
Li M, Miao Z, Tan W, Yue J, Zhang C, Lin L, Zhang X, Ding J. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clinical Cancer Research. 10: 8266-8274. PMID 15623602 DOI: 10.1158/1078-0432.Ccr-04-0951 |
0.311 |
|
| 2004 |
Liu W, Zhang Y, Shen Y, Jiang J, Miao Z, Ding J. Telomerase inhibition is a specific early event in salvicine-treated human lung adenocarcinoma A549 cells. Biochemical and Biophysical Research Communications. 323: 660-667. PMID 15369801 DOI: 10.1016/J.Bbrc.2004.08.135 |
0.321 |
|
| 2004 |
Guo X, Zhong L, Zhang X, Zhao W, Zhang X, Lin L, Ding J. Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Biochimica Et Biophysica Acta. 1673: 186-193. PMID 15279890 DOI: 10.1016/J.Bbagen.2004.04.015 |
0.358 |
|
| 2003 |
Miao ZH, Tang T, Zhang YX, Zhang JS, Ding J. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. International Journal of Cancer. 106: 108-15. PMID 12794765 DOI: 10.1002/Ijc.11174 |
0.317 |
|
| 2003 |
Tan W, Lin L, Li M, Zhang Y, Tong Y, Xiao D, Ding J. Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. European Journal of Pharmacology. 459: 255-262. PMID 12524154 DOI: 10.1016/S0014-2999(02)02848-0 |
0.319 |
|
| 2002 |
Chen X, Ding J, Ye Y, Zhang J. Bioactive abietane and seco-abietane diterpenoids from Salvia prionitis Journal of Natural Products. 65: 1016-1020. PMID 12141863 DOI: 10.1021/Np010561J |
0.306 |
|
| 2001 |
Li Y, Shan F, Wu J, Wu G, Ding J, Xiao D, Yang W, Atassi G, Léonce S, Caignard D, Renard P. Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle Bioorganic & Medicinal Chemistry Letters. 11: 5-8. PMID 11140731 DOI: 10.1016/S0960-894X(00)00578-3 |
0.315 |
|
| 1999 |
Zhang J, Ding J, Tang Q, Li M, Zhao M, Lu L, Chen L, Yuan S. Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs. Bioorganic & Medicinal Chemistry Letters. 9: 2731-2736. PMID 10509925 DOI: 10.1016/S0960-894X(99)00472-2 |
0.322 |
|
| Show low-probability matches. |